Avadel pharmaceuticals provides corporate update and reports fourth quarter and full year 2023 financial results

-- generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of lumryz™ -- -- as of january 31 st , greater than 2,200 patients enrolled in ryzup tm and more than 1,200 patients initiated therapy --
AVDL Ratings Summary
AVDL Quant Ranking